About this episode
Oct 8
TALAPRO-3 in mCSPC: Prof. Agarwal discusses the trial results
In this episode, UROONCO PCa associate editor Prof. Claudia Kesch interviews Dr. Neeraj Agarwal, from Dana-Farber Cancer Institute on the recent results of the TALAPRO-3 trial. This trial investigates the efficacy and safety of TALA + ENZA in men with mCSPC bearing HRR gene alter ... Show More
19m 30s
Oct 3
EAU Section of Urological Imaging: Small renal masses beyond surgery: Imaging, biopsy, active surveillance and ablative technologies
How can small renal masses be managed beyond surgery, and how should the most appropriate approach be selected for each patient?In this episode, Prof. Daniela Oprea-Lager (NL) is joined by Assoc. Prof. Lorenzo Bianchi (IT) and Dr. Giuseppe Basile (GB) to discuss the evolving mana ... Show More
24m 2s
Sep 26
Dr. Béatrice Bouchard discuss membranous urethral length and post-prostatectomy stress urinary incontinence
In “Membranous urethral length and post-prostatectomy stress urinary incontinence”, Dr. Béatrice Bouchard (CA) examines membranous urethral length (MUL) as a predictor of continence outcomes after prostatectomy. Based on a retrospective study of 161 men, she shows that patients w ... Show More
6m 26s
Feb 2023
Episode 223: ASCO GU 2023: Discussing KEYNOTE-057 with Andrea Necchi, MD
<p>The Uromigos met with Andrea Necchi, MD at the 2023 ASCO GU Cancers Symposium to discuss results of the phase 2 KEYNOTE-057 study on the use of pembrolizumab monotherapy for patients with high-risk non-muscle-invasive bladder cancer who are unresponsive to bacillus Calmette–Gu ... Show More
24m 27s
Sep 2024
ESMO 2024 GU Update
<p>We are doing a special episode this week to cover some of the key GU abstracts from ESMO 2024. We cover an update on the STAMPEDE prostate cancer trial, SUNNIFORECAST in non-clear cell renal cell carcinoma, SunRISe-4 in bladder cancer, and more.</p>
18m 10s
May 2024
Key Abstracts in GU Cancers at ASCO24
26m 4s
Jul 2024
Ep. 178 ASCO 2024: Game-Changing GU Oncology Updates in Bladder and Kidney Cancers with Dr. Sumanta Pal and Dr. Petros Grivas
Stay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros ... Show More
57m 23s
Aug 2025
11: Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma
The latest Oncology Decoded discussion with Manojkumar Bupathi, MD, MS, executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute (SCRI) and medical oncologist with Rocky Mountain Cancer Centers specializing in solid tumors and ... Show More
41m 45s
Oct 2025
Ep. 267 Sequencing Therapies in NMIBC Management with Dr. Mark Tyson and Dr. Suzanne Merrill
New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor ... Show More
1 h
Jun 2024
GU Oncology Highlights From ASCO24
34m 54s
Mar 2024
Episode 171: ASCO-GU Top Clinical Data With Pedro Barata
Dr. Pedro Barata, Director of the Clinical Genitourinary Medical Oncology Research Program at UH Seidman Cancer Center, provides an exclusive round-up of the most groundbreaking and practice-changing research unveiled at the ASCO GU 2024 meeting. With expertise and insight, he de ... Show More
46m 7s
Jan 2023
VERDICT analysis for prostate MRI
Dr. Refky Nicola discusses the role of Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumor (VERDICT) MRI analysis in improving the classification of clinically significant prostate cancer with Dr. Valdair Muglia. Avoiding Unnecessary Biopsy after Multiparame ... Show More
15m 6s
Sep 2024
Episode 347: ESMO 2024 - DV + Pembro in Urothelial Cancer
<p>Matt Galsky describes his ESMO 2024 abstract of disitimab vedotiin + pembrlizumab in bladder cancer</p>
17m 59s
UROONCO BCa chief editor Dr. Benjamin Pradere talks to Assoc. Prof. Andrea Necchi (IT) at EMSO 2024 on the results of the interim analysis of SunRISe-4 study: TAR-200 plus cetrelimab or CET alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy. Assoc. Prof. Nec ... Show More
<p>Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss promising combination therapies and other compelling advances in genitourinary cancers in advance of the 2024 ASCO Annual Meeting.</p> <p><span style= "text-decoration: underline;"><strong>TRANSCRIPT</strong></span></p> <p ... Show More
<p class="MsoNormal" style="text-align: justify;"><span class= "normaltextrun"><span style= "font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-ansi-language: EN-US; mso-f ... Show More
